A Phase II Study of SKB571 in Patients With Lung Cancer

Summary

This is a multicenter, phase II study. The purpose of this study is to evaluate the safety and preliminary anti-tumor activity of SKB571 in patients with advanced non-small cell lung cancer. Eligible subjects will receive SKB571 monotherapy, until radiographic disease progression, intolerable toxicity, discontinuation of study treatment required by the subject, or other protocol-specified treatment discontinuation criteria, whichever occurs first.

Timeline

Start

2026-01-19

Primary completion

2028-01-19

Completion

2028-01-19

Drugs

Indications